Reference : Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic w...
Scientific journals : Article
Human health sciences : Rheumatology
Business & economic sciences : Special economic topics (health, labor, transportation…)
http://hdl.handle.net/2268/12229
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.
English
Hiligsmann, Mickaël mailto [Université de Liège - ULg > HEC - Ecole de gestion de l'ULg > Economie industrielle >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2010
Osteoporosis International
Springer Science & Business Media B.V.
21
157-165
Yes (verified by ORBi)
International
0937-941X
1433-2965
Godalming
United Kingdom
[en] cost-effectiveness ; microsimulation ; osteoporosis ; postmenoapusal osteoporosis ; strontium ranelate
[en] The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women. INTRODUCTION: This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporotic women. METHODS: A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score </= -2.5 SD or with prevalent vertebral fractures. The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment. Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analyses. RESULTS: Strontium ranelate was cost-saving at the age of 80 years in both populations. For women with a T-score </= -2.5 SD, the costs per QALY gained of strontium ranelate were respectively <euro>15,096 and <euro>6,913 at 70 and 75 years of age while these values were <euro>23,426 and <euro>9,698 for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions. CONCLUSION: This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporotic women.
Researchers ; Professionals
http://hdl.handle.net/2268/12229
10.1007/s00198-009-0924-z

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
OI_hiligsmann.pdfPublisher postprint169.2 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.